A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 28 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $185.0, with a high of $235.00 and a low of $128.00. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting diverse opinions on the company's future performance.
August 15, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sarepta Therapeutics has received mixed analyst ratings over the past three months, with an average 12-month price target of $185.0. Recent actions include both raises and lowers in ratings and price targets, indicating diverse opinions on the company's future performance.
The mixed analyst ratings and recent changes in price targets suggest uncertainty about Sarepta Therapeutics' short-term performance. The average price target has increased, but the diverse opinions indicate a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100